Filter Results:
(484)
Show Results For
- All HBS Web (484)
- Faculty Publications (183)
Show Results For
- All HBS Web (484)
- Faculty Publications (183)
- 01 Mar 2016
- News
Off Script
according to one study—and the limited lifespan of patent rights. What can the pharmaceutical industry and government regulators do to improve conditions? We put your queries to Fred Hassan (MBA 1972), a managing director at Warburg... View Details
- 18 Sep 2014
- News
Room to grow: global expansion in the middle ground
global players with hundreds of millions, and sometimes billions, of dollars in sales. Their middle-ground strategies emerged from Israel’s small size, relative isolation, and cadre of executives accustomed to military maneuvering. Ofek, who conducted his View Details
- 28 Sep 2020
- Working Paper Summaries
What Can Economics Say About Alzheimer's Disease?
- February 2009
- Teaching Note
Syndexa and Technology Transfer at Harvard University (TN)
Teaching Note for [808073]. View Details
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details
Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
- 25 Jul 2005
- Research & Ideas
An Organization Your Customers Understand
and intensive retail marketing programs. Hospitals, pharmacies, and research scientists are managed as constituents; efforts are made to ensure only that they feel fairly treated in their transactions with the firm. The View Details
Keywords: by Robert Simons
- 01 Mar 2007
- News
In Brief
Q&A with Daniel Vasella. Initially regarded by critics as too inexperienced to lead a major pharmaceutical company, Daniel Vasella (PMD 57, 1989) has set a new standard for innovation as CEO of Novartis. The Winning Season. Last year, St.... View Details
- February 2000 (Revised June 2003)
- Case
Pepcid AC: Racing to the OTC Market
By: Charles King III, Alvin J. Silk, Ernst R. Berndt and Lisa R. Klein
Pepcid management must decide whether to risk all in a race to be first in the over-the-counter market with a new heartburn remedy. View Details
Keywords: Competitive Advantage; Product Positioning; Markets; Research; Marketing Strategy; Product Development; Decision Choices and Conditions; Pharmaceutical Industry
King, Charles, III, Alvin J. Silk, Ernst R. Berndt, and Lisa R. Klein. "Pepcid AC: Racing to the OTC Market." Harvard Business School Case 500-073, February 2000. (Revised June 2003.)
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
Now that scientists have mapped the human gene, can drug makers map a road to unlimited riches? For John Lechleiter, Executive Vice President of Eli Lilly and Company's Pharmaceutical Products and Corporate Development, there remain more... View Details
Keywords: by Sean Silverthorne
- Web
Kraft Accelerator
What are Disease Foundation Leaders Focused on Right Now? (pdf) HBS Kraft Precision Medicine Accelerator How Nonprofit Foundations Can Sustainably Fund Disease Research Harvard Business Review What It Takes to Lead a Disease View Details
John G. Searle
The pharmaceutical company that John Searle inherited from his father was moderately successful, with about $1 million in sales in 1936, but under Searle’s guidance the company grew rapidly. G. D. Searle’s biggest growth is owed to the... View Details
Keywords: Healthcare
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly... View Details
Keywords: Health; Economics; Government and Politics; Innovation and Invention; Research; Science; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
- Fast Answer
Investing in Life Sciences - SIP Resources
Market research: BCC Research - Reports on major economic, scientific, and technological developments in industrial, pharmaceutical, and high technology worldwide. Frost & Sullivan - Reports and market trends encompassing various... View Details
- 06 Feb 2007
- First Look
First Look: February 6, 2007
inventors, including knowledge spillovers and agglomeration and the concentration of spinoffs. This work investigates a possible antecedent of inventor mobility: regional variation in the enforcement of postemployment non-compete covenants. While previous View Details
Keywords: Martha Lagace
- 24 Apr 2014
- News
Giving hope and inspiration to cancer patients around the globe
Every new day is a good day for Kathryn E. Giusti (MBA 1985) since that morning in 1996 when her oncologist told her to get her affairs in order because she had a rare blood cancer, with three years to live. Leveraging her past experience as a View Details
- 01 Mar 2017
- News
How Deep Brain Stimulation Could Change Medicine
psychiatric patients. This targeted approach gives Bennet hope that Harmoni can benefit not only people suffering from movement disorders, but also a whole class of psychiatric patients. But working under Bennet and his collaborator, neurosurgeon Kendall Lee, a team of... View Details
Keywords: Janelle Nanos
- 15 Dec 2024
- News
After Ozempic
Back before Ozempic, when Kate Mulroney (MBA 1984) spoke at technical conferences about her work at Novo Nordisk, people often assumed she was talking about Novartis. “I’d have to explain that’s a Swiss company; we’re Danish,” says Mulroney, now head of advanced... View Details
- Student-Profile
Byungyeon Kim
important Harvard’s worldwide research centers would be to his work. His second year research project involved a study of sales force compensation that resulted from a partnership with a Turkish View Details
- 06 May 2008
- First Look
First Look: May 6, 2008
company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing... View Details
Keywords: Martha Lagace
- 01 Jan 2002
- News
Raymond V. Gilmartin (MBA '68)
the business world has an important leadership role to play in terms of closing the gap in health and other vital social issues," he says. When Ray Gilmartin joined Merck in June 1994 as president and CEO (he became chairman several months later), it was the first time... View Details